{"id":540030,"date":"2021-04-22T17:44:02","date_gmt":"2021-04-22T17:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=540030"},"modified":"2021-04-22T17:44:02","modified_gmt":"2021-04-22T17:44:02","slug":"chronic-hepatitis-delta-virus-infection-market-size-share-trends-epidemiology-and-competitive-analysis-report-2030-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/chronic-hepatitis-delta-virus-infection-market-size-share-trends-epidemiology-and-competitive-analysis-report-2030-delveinsight_540030.html","title":{"rendered":"Chronic Hepatitis Delta Virus Infection Market Size & Share, Trends, Epidemiology and Competitive Analysis Report 2030 | DelveInsight"},"content":{"rendered":"
\"Chronic<\/a><\/p>\n
\n
DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s “Chronic Hepatitis Delta Virus (HDV) Infection – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Hepatitis Delta Virus (HDV) Infection, historical and forecasted epidemiology as well as the Chronic Hepatitis Delta Virus (HDV) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.\n<\/div>\n

Hepatitis delta, also known as hepatitis D or HDV is a liver infection caused by the hepatitis delta virus that results in the most severe form of viral hepatitis known to humans. However, only those already infected with hepatitis B can acquire hepatitis delta, as it is dependent on the hepatitis B virus to reproduce.<\/p>\n

The HDV infection is of two types: superinfection and co-infection. Super infections occur when a person with chronic hepatitis B becomes infected with hepatitis delta. These types of infections are more common and have a 70\u201290% chance of resulting in a chronic infection of both hepatitis B and delta. Co-infections occur when a person gets infected with hepatitis B and delta at the same time, and have a <5% chance of resulting in chronic infections.<\/p>\n

DelveInsight’s “Chronic Hepatitis Delta Virus (HDV) Infection Market Report 2030<\/strong><\/a>“<\/strong> delivers an in-depth understanding of the Chronic Hepatitis Delta Virus (HDV) Infection, historical and forecasted epidemiology as well as the Chronic Hepatitis Delta Virus (HDV) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

Request for sample pages: <\/strong>https:\/\/www.delveinsight.com\/sample-request\/chronic-hepatitis-delta-virus-infection-market<\/strong><\/a><\/p>\n

Chronic Hepatitis Delta Virus (HDV) Infection Disease Understanding and Treatment Algorithm<\/strong><\/p>\n

HDVC is percutaneously or sexually transmitted through contact with infected blood or blood products. Vertical transmission is possible, but rare. Chronic liver disease, which may occur with hepatitis D, often has minimal symptoms. At times there may be mild flare-ups with jaundice, nausea, fatigue, and weight loss.<\/p>\n

There are at least eight different types of hepatitis delta called “genotypes,” which are associated with distinct disease progression. In general, a more severe condition occurs in genotype 1 and 3, and milder in genotype 2. Generally, a single genotype tends to dominate in an infected person, but multiple genotypes can occur in those at high risk of repeated exposure to the virus.<\/p>\n

The diagnosis will require two tests, namely the hepatitis delta antibody (Anti-HDV total) and the hepatitis delta RNA (HDV RNA). The HDV antibody total test is the first step, as people who have recovered from or are currently infected with hepatitis delta will have antibodies. If the HDV antibody total test is positive, it should be followed by the HDV RNA test to confirm an active infection. If this test is negative, a current infection is unlikely.<\/p>\n

Chronic Hepatitis Delta Virus (HDV) Infection Epidemiology  <\/strong><\/p>\n

It is estimated that globally, approximately 5% of people with chronic HBV infection are co-infected with HDV, resulting in a total of 15\u201220 million persons infected with HDV worldwide. The high-prevalence areas include Africa, Asia, Pacific Islands, Middle East, Eastern Europe, South America, and Greenland. Superinfections<\/strong> have a 70\u201290%<\/strong> chance of resulting in a chronic infection <\/strong>of both hepatitis B and delta. Coinfections<\/strong> have a <5%<\/strong> chance of resulting in chronic infections<\/strong>.<\/p>\n

The Chronic Hepatitis Delta Virus (HDV) Infection epidemiology<\/strong> division provide insights about historical and current Chronic Hepatitis Delta Virus (HDV) Infection <\/strong>patient pool and forecasted trend for every seven major countries.<\/p>\n

Key Findings<\/strong><\/p>\n

According to the study by Gaeta et al., <\/strong>titled “Chronic Hepatitis D: A Vanishing Disease? An Italian Multicenter Study,” the prevalence of anti-HDV among HBV carriers with liver disease decreases from 25% in 1983 to 14% in 1992 in Italy and from 15.1% to 7.1% in Spain.<\/p>\n

Download sample pages: <\/strong>https:\/\/www.delveinsight.com\/sample-request\/chronic-hepatitis-delta-virus-infection-market<\/strong><\/a><\/p>\n

Chronic Hepatitis Delta Virus (HDV) Infection Drug Chapters<\/strong><\/p>\n

The current clinical pipeline of chronic HDV infection is weak. The key players that are working toward the development of therapies for chronic HDV infection are MYR Pharmaceuticals<\/strong> and Eiger BioPharmaceuticals<\/strong>.<\/p>\n

Drug chapter segment of the Chronic Hepatitis Delta Virus (HDV) Infection market report<\/strong> <\/a>encloses the detailed analysis of Chronic Hepatitis Delta Virus (HDV) Infection marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs.<\/p>\n

Chronic Hepatitis Delta Virus (HDV) Infection Market Outlook<\/strong><\/p>\n

Currently, no treatment has been approved <\/strong>by the US FDA for chronic HDV infection. As HDV requires HBV for its replication, it can be prevented<\/strong> by the use of hepatitis B vaccine<\/strong>.<\/p>\n

The treatment recommendations to date are based on the experience with IFN-based therapy<\/strong>. Current guidelines of the American Association for the Study of Liver Diseases (AASLD), Asian Pacific Association for the Study of the Liver (APASL), and the European Association for the Study of the Liver (EASL) recommend peg-IFN-α for 12 months in patients with compensated liver disease with consideration of nucleoside and nucleotide analogue therapy with ongoing HBV DNA replication, and referral to specialized centers for experimental therapies given limited efficacy of pegylated interferon-<\/strong>α<\/strong> (peg-IFN-<\/strong>α<\/strong>)<\/strong>.<\/p>\n

IFN-α, peg-IFN-α, and combination therapy with nucleoside or nucleotide analogues have been studied in chronic HDV infection, but therapy with IFN is largely limited to patients who are non-cirrhotic.<\/p>\n

Novel treatment options have been evaluated recently, and four areas of interest include drugs that target entry, assembly and release of viral particles in addition to treatment that activates the immune host response. The use of HBV nucleoside <\/strong>and nucleotide analogue <\/strong>as monotherpay or in combination with IFN-α therapy has been explored in chronic HDV infected patients.<\/p>\n

The Chronic Hepatitis Delta Virus (HDV) Infection market outlook<\/strong><\/a> of the report helps to build the detailed comprehension of the historic, current, and forecasted Chronic Hepatitis Delta Virus (HDV) Infection <\/strong>market <\/strong>trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. <\/p>\n

According to DelveInsight, Chronic Hepatitis Delta Virus (HDV) Infection <\/strong>market in 7MM is expected to change in the study period 2017-2030.<\/p>\n

Request for sample pages of the report: <\/strong>https:\/\/www.delveinsight.com\/sample-request\/chronic-hepatitis-delta-virus-infection-market<\/strong><\/p>\n

Table of contents<\/strong>
1 Key Insights
2 Executive Summary of Chronic Hepatitis Delta virus infection
3 Chronic Hepatitis Delta virus infection Market Overview at a Glance
4 Disease Background and Overview: Chronic Hepatitis Delta virus infection
5 Case Reports
6 Chronic Hepatitis Delta virus infection Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Chronic Hepatitis Delta virus infection Treatment and Medical Practices
11 Unmet needs
12 Chronic Hepatitis Delta virus infection Marketed Drugs
13 Chronic Hepatitis Delta virus infection Emerging Drugs
14 Chronic Hepatitis Delta virus infection 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Chronic Hepatitis Delta virus infection Market Drivers
19 Chronic Hepatitis Delta virus infection Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight<\/p>\n

About DelveInsight<\/strong>
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.<\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Yash Bhardwaj
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> 9193216187
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> NV
Country:<\/strong> United States
Website:<\/strong> www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

DelveInsight Business Research LLP DelveInsight’s “Chronic Hepatitis Delta Virus (HDV) Infection – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Chronic Hepatitis Delta Virus (HDV) Infection, historical and forecasted epidemiology as well as the Chronic … Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-540030","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/540030","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=540030"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/540030\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=540030"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=540030"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=540030"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}